A Phase 1 interventional study of ACT-541468 and ACT-541468 placebo in Healthy, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-15.
Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A study to investigate the drug-drug interactions between ACT-541468 and ethanol in healthy subjects
Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 h i.v. ethanol clamp at a level of 0.6 g/L in combination with a single oral dose of ACT-541468 (50 mg)
Drug: ACT-541468 · Other: Ethanol 10%
5 h i.v. placebo clamp in combination with a single oral dose of ACT-541468 (50 mg)
Drug: ACT-541468 · Other: Ethanol placebo
5 h i.v. ethanol clamp at a level of 0.6 g/L in combination with a single oral dose of matching ACT-541468 placebo
Other: ACT-541468 placebo · Other: Ethanol 10%
5 h i.v. placebo clamp in combination with a single oral dose of matching ACT-541468 placebo
Other: ACT-541468 placebo · Other: Ethanol placebo
One tablet of 50 mg ACT-541468 will be administered orally.
Matching ACT-541468 placebo will be administered orally as 1 tablet.
Ethanol 10% w/v solution in 5% glucose will be administered i.v. for 5 h and clamped at an ethanol level of 0.6 g/L.
Matching placebo for the ethanol infusion (i.e., 5% glucose solution) will be administered i.v. for 5 h.
Change from baseline for saccadic peak velocity (degrees/sec) to assess sedation
Time frame: Several timepoints on Day 1; for up to 24 hours post-dose
Change from baseline for smooth pursuit (%) to assess eye movement coordination and attention
Time frame: Several timepoints on Day 1; for up to 24 hours post-dose
Change from baseline for adaptive tracking (%) to assess visuo-motor control and vigilance
Time frame: Several timepoints on Day 1; for up to 24 hours post-dose
Change from baseline for body sway (antero-posterior in mm / 2 min) to assess postural stability
Time frame: Several timepoints on Day 1; for up to 24 hours post-dose
Change from baseline for visual analog scales (VAS) Bond & Lader to assess subjective alertness, mood, and calmness
Time frame: Several timepoints on Day 1; for up to 24 hours post-dose
Change from baseline for VAS for alcohol intoxication to assess subjective effects of ethanol
Time frame: Several timepoints on Day 1; for up to 24 hours post-dose
ACT-541468 PK endpoints for treatments A and B: Area under the plasma concentration-time curve (AUC) from time zero to 24 h (AUC0-24)
Time frame: Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose
ACT-541468 PK endpoints for treatments A and B: AUC from zero to infinity (AUC0-∞)
Time frame: Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose
ACT-541468 PK endpoints for treatments A and B: Maximum plasma concentration (Cmax)
Time frame: Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose
ACT-541468 PK endpoints for treatments A and B: Time to reach Cmax (tmax)
Time frame: Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose
ACT-541468 PK endpoints for treatments A and B: Terminal elimination half-life (t½)
Time frame: Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose
Ethanol PK endpoints for treatments A and C: Breath ethanol concentrations (BrEC)
Time frame: Several timepoints on Day 1; for up to 24 hours post-dose
Ethanol PK endpoints for treatments A and C: Total ethanol dose (in grams) required to maintain the 0.6 g/L ethanol clamp
Time frame: Several timepoints on Day 1; for up to 5 hours
Safety endpoints: Treatment-emergent AEs from study treatment administration up to EOT in each treatment period
Time frame: AEs from Day 1 to Day 2 (EOT/EOS); for up to 2 days post-dose
Safety endpoints: Treatment-emergent SAEs from study treatment administration up to EOT in each treatment period
Time frame: SAEs from Screening to Safety follow up; for up to 14 weeks
Plan to share: No
Ran from Aug 2018 to primary completion in Oct 2018, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daridorexant
Idorsia Pharmaceuticals Ltd. →